Bioventus Inc. (NYSE:BVS) SVP Sells $26,693.55 in Stock

Bioventus Inc. (NYSE:BVS) SVP Katrina J. Church sold 2,535 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $26,693.55. Following the sale, the senior vice president now directly owns 47,264 shares of the company’s stock, valued at approximately $497,689.92. This represents a 5.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bioventus Stock Down 3.5 %

Shares of Bioventus stock opened at $10.62 on Friday. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38. The company has a market cap of $861.87 million, a P/E ratio of -17.41 and a beta of 0.79. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The stock has a 50-day moving average price of $11.81 and a 200 day moving average price of $9.82.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The company had revenue of $138.96 million during the quarter, compared to analysts’ expectations of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same period in the prior year, the business earned $0.05 earnings per share. As a group, analysts expect that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Bioventus

Several large investors have recently added to or reduced their stakes in BVS. Virtus Fund Advisers LLC bought a new position in Bioventus in the third quarter worth $42,000. Quest Partners LLC acquired a new position in Bioventus in the third quarter worth about $51,000. Quarry LP acquired a new position in Bioventus in the third quarter worth about $59,000. HB Wealth Management LLC bought a new position in Bioventus during the second quarter worth about $60,000. Finally, Covestor Ltd acquired a new stake in Bioventus during the third quarter valued at approximately $69,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th. Craig Hallum boosted their price target on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th. Finally, Canaccord Genuity Group raised their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.